TY  - CONF

T1  - Abstract OT1-04-05: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor–positive breast cancer and bone metastases

JO  - Ongoing Clinical Trials

PY  - 2017/02/01

AU  - Rugo HS

AU  - Drumea KC

AU  - Campone M

AU  - Barnadas A

AU  - Petrenciuc O

AU  - Zhang A

AU  - Li R

AU  - Coleman RE

ED  - 

DO  - DOI: 10.1158/1538-7445.sabcs16-ot1-04-05

PB  - American Association for Cancer Research

Y2  - 2025/10/10

ER  -